D

DaShenLin Pharmaceutical Group Co Ltd
SSE:603233

Watchlist Manager
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Watchlist
Price: 15.3 CNY -5.9% Market Closed
Market Cap: 17.4B CNY
Have any thoughts about
DaShenLin Pharmaceutical Group Co Ltd?
Write Note

DaShenLin Pharmaceutical Group Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

DaShenLin Pharmaceutical Group Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
D
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Cash & Cash Equivalents
ÂĄ2.8B
CAGR 3-Years
7%
CAGR 5-Years
19%
CAGR 10-Years
N/A
LBX Pharmacy Chain JSC
SSE:603883
Cash & Cash Equivalents
ÂĄ768.3m
CAGR 3-Years
-9%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Yifeng Pharmacy Chain Co Ltd
SSE:603939
Cash & Cash Equivalents
ÂĄ3B
CAGR 3-Years
22%
CAGR 5-Years
20%
CAGR 10-Years
N/A
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
Cash & Cash Equivalents
ÂĄ829.9m
CAGR 3-Years
44%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
Cash & Cash Equivalents
ÂĄ2.8B
CAGR 3-Years
18%
CAGR 5-Years
14%
CAGR 10-Years
8%
A
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
Cash & Cash Equivalents
ÂĄ580.7m
CAGR 3-Years
115%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

DaShenLin Pharmaceutical Group Co Ltd
Glance View

Market Cap
17.4B CNY
Industry
Retail

DaShenLin Pharmaceutical Group Co., Ltd. engages in the retail and wholesale of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong and currently employs 38,353 full-time employees. The company went IPO on 2017-07-31. The firm's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The firm mainly conducts its business within domestic market.

Intrinsic Value
44.52 CNY
Undervaluation 66%
Intrinsic Value
Price
D

See Also

What is DaShenLin Pharmaceutical Group Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.8B CNY

Based on the financial report for Jun 30, 2024, DaShenLin Pharmaceutical Group Co Ltd's Cash & Cash Equivalents amounts to 2.8B CNY.

What is DaShenLin Pharmaceutical Group Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
19%

Over the last year, the Cash & Cash Equivalents growth was 6%. The average annual Cash & Cash Equivalents growth rates for DaShenLin Pharmaceutical Group Co Ltd have been 7% over the past three years , 19% over the past five years .

Back to Top